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Summary.-Serum angiotensin-converting enzyme (SACE) was analysed in 27
patients with Hodgkin's disease, 25 with non-Hodgkin lymphoma, 14 with acute
leukaemia, 15 with chronic leukaemia, and 15 with multiple myeloma. SACE was
depressed in these patients as a whole, with a mean level of 19 9 u/ml, compared with
116 healthy controls (mean 24-4 u/ml, P<0001). This depression was greatest in
chronic leukaemia and multiple myeloma. In Hodgkin's disease no relationship was
found between enzyme activity and stage, activity, histopathology, treatment,
mediastinal involvement or prognosis.
In non-Hodgkin patients a poor prognosis was generally associated with low
SACE activity. The low SACE activity was not related to recent corticosteroid treat-
ment, and the cause and pathophysiological significance is unexplained.
Since SACE is high in the granulomatous disorder sarcoidosis (which can mimic
malignant lymphnode and blood diseases) SACE analysis can be valuable in
evaluating patients with mediastinal lymphadenopathy and those in whom non-
caseating epithelioid granulomas are found.
ANGIOTENSIN - CONVERTING ENZYME
(ACE, kininase II) is a membrane-bound
glycoprotein which converts angiotensin I
to angiotensin II, and participates in
bradykinin degradation. Although the
enzyme is always found in endothelial
cells, the greatest amount and activity
occurs in the endothelium of lungs (Soffer,
1976).
In the granulomatous multisystem
disease sarcoidosis, serum-ACE (SACE)
has been found to be high (Lieberman,
1975; Silverstein et al., 1977). The finding
of a high ACE activity in sarcoid lymph
nodes (Silverstein et al., 1976) and the
demonstration of ACE in sarcoidosis
epithelioid cells (Silverstein et al., 1979)
point to the monocyte-macrophage-
derived epithelioid-cell granuloma as the
source of high SACE in sarcoidosis.
The reasons for investigating SACE in
malignant lymphomas, leukaemia and
multiple myeloma were:
Diagnostic. In subacute sarcoidosis
hilar and mediastinal lymphnode enlarge-
ment with or without pulmonary infiltra-
tions are typical; but a similar picture can
in fact also be caused by malignant
diseases. Furthermore, non-caseating
granulomas may be seen in up to 20% of
patients with Hodgkin's disease (Neiman,
1977; Whittaker et al., 1978).
Pathophysiological. Sarcoidosis and
Hodgkin's disease share some common
features: granuloma formation, impair-
ment of delayed immune reactions (Chase,
1966), monocyte activation (Kitahara et
al., 1979; Douglas et al., 1976) and in-
creased production of leucocyte-migration
inhibitory factors (MIF; Yoshida et al.,
1 979).
Furthermore, coexistent sarcoidosis and
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Hodgkin's disease has been described
(Goldfarb & Cohen, 1970) and it has been
proposed that malignant lymphomas occur
more frequently among sarcoidosis
patients than expected (Brincker & Wil-
bek, 1974) although recent evidence speaks
against this (R0mer, 1980b).
We therefore found it appropriate to
examine a series of Hodgkin's disease
patients, as the main purpose ofthe study.
Additionally, patients with non-Hodgkin
lymphoma, leukaemia and multiple
myeloma were examined for comparison,
because all these diseases affect the
lymphoproliferative and reticulo-endothe-
lial systems.
MATERIALS AND METHODS
Patients.-The series consisted of 96
patients (Table I). All underwent routine
investigation including haematological and
biochemical profile, marrow aspiration and
X-ray examination of the lungs. Patients
with malignant lymphomas were subjected to
lymphangiography, liver and bone scans. In
many cases of Hodgkin's disease, explorative
laparotomy was performed. All patients had
normal kidney function.
Patients with Hodgkin's disease were
staged according to the Ann Arbor Interna-
tional Convention (Carbone et al., 1971).
"Treated" patients were under treatment
with prednisone and/or cytostatics at ex-
amination, or had stopped treatment less
than 2 months before. This limit was chosen
because the primary aim of the study was to
examine the influence on enzyme activity of
the disease itself. Some patients received
large intermittent doses of steroid therapy
and it was necessary to choose a relatively
long period free ofmedication before we could
state that a given patient was "without treat-
ment".
SACE analysis.-The analysis was per-
formed bythespectrophotoinetricmethoddes-
cribed by Cushman & Cheung (1971) as modi-
fied by Lieberman (1975) and including the
correction factor reported later (Lieberman,
1976).
Statistics.-Student's t test was used to
examine differences between SACE inpatients
and controls. Difference ofSACE in subgroups
was analysed by the Mann-Whitney rank-
sum test. Difference of frequencies was
analysed with Fisher's exact test (small
samples) or x2 test with Yates' correction.
Significance level was 5%.
RESULTS
Normal range in our laboratory among
116 healthy adults aged 18-65 years was
12-0-36-8 u/ml (mean + 2 s.d.; R0mer,
1979).
Table I demonstrates that all groups of
patients had more or less depressed SACE
activity when compared with healthy con-
trols, the depression being greatest in
chronic leukaemia. SACE among all 96
patients was 19-9 u/ml + 6-8 (s.d.), sig-
nificantly lower than in healthy controls
(P < 0-001).
In an attempt to evaluate relationships
between SACE and some clinical variables,
patients with Hodgkin's disease were
further examined with respect to disease
activity, treatment, staging, histopath-
ology and intrathoracic involvement
(Table II). No differences between the
subgroups were significant.
In the whole series only one patient
(with Hodgkin's disease) had a slightly
raised SACE (39-2 u/ml) on one occasion.
At re-examination 2 months later, SACE
was in the higher normal range (34.0 u/ml).
The only patient in whom non-caseating
epitheloid granulomas were found had
normal SACE.
Similar analyses in the 69 patients with
non-Hodgkin malignant diseases produced
no consistent pattern, except in respect of
prognosis. Especially, no significant differ-
ence was found whether or not the
patients were recently treated with pred-
nisone (e.g. actually being treated or
treated within 2 months of examination);
SACE was 19-1 u/ml + 6-6 in 23 patients
in prednisone treatment and 21-2 u/ml+
6-8 in 46 patients not receiving prednisone.
Furthermore, there was no difference in
SACE between acute and chronic leuk-
aemia, or between leukaemias of myeloid
or lymphoid origin.
As mentioned above, mean SACE was
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TABLE I.-Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and
multiple myeloma
pal
Healthy controls
Hodgkin's disease
Non-Hodgkin lymphoma
Acute leukaemia
Chronic leukaemia
Multiple myeloma
* 39-2 u/mI on one occasion.
No. of
tients Mean
L16 40
27 42
25 52
14 40
15 55
15 64
TABLE II.-SACE in Hodgkin's disease
according to clinical and pathological
features
SACE (u/ml)
No. of ,
patients Mean S.d.
Activity
Active disease:
untreated 12 19-9 7-7
treated 6 23-2 8-4
Patients in remission* 9 21-5 6-2
Stage
I 3 (I)t 15-0 2-3
II 10 (4) 23-6 6-8
III 8 (1) 18-7 7-1
IV 0
Unclassified* 6 (3) 23-7 6-4
Histopathological classification
Lymphocyte predominance 5 (1) 22-1 9-7
Mixed cellularity 3 (1) 25-9 0-7
Nodular sclerosis 12 (3) 19-9 7-3
Lymphocyte depletion 0
Unclassified* 7 (4) 20-0 6-9
Mediastinal/pulmonary involvement at examination
With 13 22-3 7-5
Without 14 19-6 7-0
* High SACE (39-2 u/ml) on one occasion. The
patient had lung fibrosis following radiation.
t No. in remission at time ofexamination.
generally low in patients with the
malignant diseases under discussion. The
figures in Table III demonstrate that the
percentage of depressed SACE (i.e. < 12-0
u/ml)among these patients was signi-
ficantly more than in controls.
This was most pronounced in patients
with leukaemia and myeloma. In the latter
group an extremely low SACE activity was
noticed at first in 3 patients hospitalized
with end-stage disease, SACE being 11-1,
11-2 and 8-3 u/ml. They contrasted with
the myeloma patients examined later, who
were outpatients in relatively good health
TABLE III.-Frequency of low SACE
No.
of
patients
Hodgkin's disease 27
Non-Hodgkin
lymphoma 25
Acute leukaemia 14
Chronic leukaemia 15
Multiple myeloma 15
Total 96
Healthy controls 116
No.
with
SACE
<12-0
u/ml
o/
/O
990
Confidence
limits
4 15
3
3
6
3
12
21
40
20
18 19 (9-7-31-0)
2 1-7 (0-1-7-5)
and with a near-normal SACE (mean 22-0
u/ml, range 14-6-27-6).
We therefore examined the relationship
between SACE activity and mortality over
3 and 12 months in non-Hodgkin patients,
to determine whether low SACE was
related to poor prognosis in general.
The results are shown in Table IV.
Regarding the whole series, mean SACE
was significantly lower in patients who
expired within 3 months than in the sur-
viving patients. Furthermore, in patients
with chronic leukaemia and multiple
myeloma who died within 3 months and
12 months respectively, all had a signifi-
cantly lower enzyme activity than sur-
vivors.
Amongst all patients with SACE below
the normal range (12-0 u/ml) there was a
significantly higher mortality after 3
months and one year than in other patients
(Table V).
DISCUSSION
The finding of a low SACE in malignant
diseases ofblood and lymphatic tissue is in
Age
Range
18-65
19-70
13-83
10-75
28-84
32-80
SACE (u/ml,
mean +s.d.)
24-4 + 6-4
21-1+8-1
20-7+5-8
18-8+ 7-0
16-7+6-4
19-3+5-8
p
(vs controls)
<0-05
<0-05
< 0-005
< 0-005
<0-05
No. with
high
SACE
1
1*
0
0
0
0
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TABLE IV.-SACE and survival
Outcome after 3 montlhs
I)ea(d AliVe
SACE t/mi + S(1.
(No.) (No.)
Hodgkin's disease 27 18-5+8-1
(3)
Non-Hodgkin lymphoma 25 20-7 + 5-6
(6)
Act(te leuikaemia
C'hironic leukaemia
Mulwlltiple myeloma
Total
14 17-9+ 7-0
(6)
1.5 10-2+0-7
(4)
15 14-1 +4-6
(4)
96 16-7+7-0
(23)
22-3 + 7-3
(24)
20-6+6-0
(19))
20-8+6-5
(8)
18-9+5-8
(1 )
Outcome after one year
Dead Alive
SACE (u/m1+s.d.)
1'* (No.)
n.s. 21-2 + 6-9 21-8 + 7-6
(6) (21)
n.s. 22-1 + 5-3
(10)
n.s. 17-1 + 6 0
(9)
19-5 + 6-2
(15)
22-0 + 6-9
(5)
P<0-01 13-4+5-1 19-4+6-0
(7) (8)
21-5+4-4 P<0-01 13-5+4-3 21-6+4-3
(11) (5) (10)
20-8+6-5
(73)
1' < 005t 18-2 + 7-0 21-0 + 6-6
(37) (59)
n.s.
n.s.
n.s.
P < 0-05
P < 0-01
n.s.t
* Alann-W'lhitney rankz-sum test. t Sttu(denit's t test.
part agreement with that of Lieberman et.
al. (1979), who found a slightly decreased
SACE in 19 patients with Hodgkin's
disease, but reported normal SACE in 11
patients with lymphocytic leukaemia and
high SACE in 3/11 patients with Lennerts
lymphoma (not represented in the present
series).
The results of the present paper con-
trast with the high SACE reported in
sarcoidosis, and they underline the differ-
ence between the nature ofsarcoidosis and,
for example, Hodgkin's disease. In sar-
coidosis, the frequency of high SACE has
been reported from 29% (Turton et al.,
1979) to about 60% (Lieberman et al.,
1979) depending on the composition of the
series in respect of race, disease activity
and duration ofdisease. Thus our previous
results suggest an association between
SACE and duration ofdisease and activity
among 85 sarcoidosis patients; 20 patients
with active disease for more than 2 years
before examination had an SACE of 49-0
u/ml + 12-7 (s.d.) and high SACE in 85%
of the patients, in contrast to 35 patients
with sarcoidosis for less than 2 years,
where SACE was high in 49%O, with a
mean of 40.1 u/ml + 15 9 (R0mer, 1]979).
Besides sarcoidosis, only Gaucher's
disease has been consistently related to
22
TABLE V.-Survival of 96 patients with
malignant lymphomas, leukaemia and
multiple myeloma, related to frequency of
SACE < 12-0 u/ml
SACE < 12-0 u/mI
(n = 18)
SACE > 12-0 u/ml
(n=78)
Total
p
At 3 months At 12 months
(,
Dead Alive Dead Alive
10 8 12 6
13 65 25 53
23 73 37 59
6-33
< 0-05
8-66
< 0-01
extremely high SACE activity (Lieberman
& Beutler, 1976) whereas SACE is de-
creased in lung cancer (Silverstein et al.,
1977; Lieberman et al., 1979) and un-
treated tuberculosis (Romer, 1980a). For
leprosy the results are contradictory
(Studdy et al., 1978; Lieberman et al.,
1979).
The lack ofnon-significance ofthe lower
SACE among prednisone-treated patients
does not contradict other reports on a
generally low SACE in steroid-treated non-
sarcoid patients (Turton et al., 1979). The
non-significance may be because the
"prednisone-treated" patients in the pre-
sent series included patients who had
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stopped treatment with prednisone within
2 months.
Furthermore, the results suggest that
SACE analysis may be helpful in evaluat-
ing patients with mediastinal and hilar
masses, and may give valuable information
when non-caseating epitheloid granulomas
are found.
An explanation for the low SACE in the
malignant diseases examined cannot be
given at present. The difference in SACE
between moderately healthy and ex-
tremely ill myeloma patients, and the
relationship between SACE level and
mortality in chronic leukaemia suggest
that perhaps enzyme production is re-
duced in the terminal stage of disease.
We can conclude that SACE is generally
low in the diseases examined, but without
a consistent pattern. The greatest clinical
value of SACE analysis in this context is
as a supplement to other methods of
evaluating patients with intrathoracic
lymphnode enlargement and in diagnosis
and monitoring of patients with sar-
coidosis.
This study was supported by the Danish Medical
Research Council (Statens Laegevidenskabelige
forskningsrad), Grant No. 512-15085. SACE analysis
was skillfully performe(d by laboratory technician
Kirsten Golezyk at the Research Laboratory,
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